Project Grant R21CA302807
Award Date
6/4/25
Completion Date
5/31/27
Dollars Obligated
$436K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research at Cold Spring Harbor Laboratory to develop a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The $269,280 award, spanning February 2025 to January 2027, aims to demonstrate selective covalent labeling and targeted degradation of the K-RAS(G12C) oncogenic driver, coupled with the release of cytotoxic polypharmaceuticals. The research involves synthesizing a...
This $109,906 Project Grant award from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports the development and application of novel RAS protein activity sensors and tools to uncover the mechanisms driving resistance to RAS inhibitor cancer drugs. The project aims to: (1) develop and apply RAS sensors in complex cancer cell models, (2) design RAS isoform-selective tools, and (3) profile and dissect the mechanisms underlying RAS inhibitor resistance. The...
This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports a research project at the Medical College of Wisconsin to investigate the use of EGFR inhibitors in colorectal cancer patients with mutant RAS genes. The key objectives are to: 1) Conduct functional mechanistic studies to test RAS mutants and their ability to bind the NF1 tumor suppressor for EGFR inhibitor sensitivity; 2) Pharmacologically target wild-type RAS in...
This federal Project Grant award of $636,046 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to define the oncogenic potential and therapeutic dependencies of pancreatic ductal adenocarcinoma (PDAC)-associated KRAS variants. The research aims to: 1) decipher how cell lineage impacts neoplastic transformation and molecular evolution of epithelial cells in the KRASG12R and KRASG12V mutants; 2) define the oncogenic factors...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapeutics that interfere with LCN2 and assess their efficacy as monotherapy and in combination with immune checkpoint...
This federal Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate the molecular mechanisms underlying the adeno-to-squamous transition in non-small cell lung cancer treatment. The $703,410 award, with a project period from January 16, 2025 to December 31, 2029, aims to identify vulnerabilities in the chromatin regulators driving this adaptive...
The National Cancer Institute (NCI) awarded a $267,527 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas MD Anderson Cancer Center. The grant will fund research to investigate mechanisms of resistance to KRAS G12C inhibitors in SMARCA4-mutant lung cancer, and explore the potential of SMARCA2-targeting small molecules to overcome this resistance. Key planned activities include molecular characterization of SMARCA4 mutant models, development of...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
The federal Project Grant award of $924,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by the Sloan-Kettering Institute for Cancer Research to develop therapeutic strategies for targeting diverse KRAS mutations in lung cancer. The award has a performance period of June 1, 2025 to May 31, 2028. As a leading comprehensive cancer center, the Sloan-Kettering Institute has extensive...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on developing innovative RNA nanoparticle and exosome-based technologies to silence the KRAS gene and inhibit metastatic colon cancer. The total award of $497,002 will support research at The Ohio State University, with sub-awards to the University of Houston and the University of Kentucky, to investigate mechanisms for delivering the CRISPR-dCas9-HDAC1 repressor complex and KRAS...